The achievement of sustainable development in Kenya has been hindered by the prevalence of HIV. The effects of HIV on sustainable development have been given less academic attention. HIV prevalence prevents people from achieving good health and well-being, which then makes them unable to conduct activities that lead to sustainable economic growth. The paper found that the prevalence of HIV causes economic hardship, destroys human capital development and human resources by reducing life expectancy and increasing mortality rates. It was equally found that the prevalence of HIV undermines social stability and mobility, reduces economic investments, influences food insecurity and makes people vulnerable. The paper found that the prevalence of HIV reduces labor supply and productivity, increases the cost of health services, promote inequality and poverty. The paper found that the prevalence of HIV was caused by the failure to integrate religion, culture and science infrastructure to achieve a holistic treatment acceptance and adherence that would overcome all misconceptions people have towards the disease. The paper found that while science provides effective HIV treatments, religious and cultural perspectives often shape community attitudes toward the disease. It was found that engaging religious and cultural as well as health workers or health advocates can help reduce stigma and promote ART adherence by aligning treatment messages with faith-based principles. The paper found that the integration that incorporates religion, culture, and science into HIV interventions would promote a more inclusive healthcare system that respects diverse beliefs while ensuring evidence-based treatment is accessible and widely accepted. The study was conducted through a qualitative methodology. Data was collected from secondary sources that included published articles, books and occasional papers as well as reports. Collected data was interpreted and analyzed through document analysis techniques.

In this review are developed insights from the current research work to develop the concept of functional materials. This is understood as real modified substrates for varied applications. So, functional and modified substrates focused on nanoarchitectures, microcapsules, and devices for new nanotechnologies highlighting life sciences applications were revised. In this context, different types of concepts to proofs of concepts of new materials are shown to develop desired functions. Thus, it was shown that varied chemicals, emitters, pharmacophores, and controlled nano-chemistry were used for the design of nanoplatforms to further increase the sizes of materials. In this regard, the prototyping of materials was discussed, affording how to afford the challenge in the design and fabrication of new materials. Thus, the concept of optical active materials and the generation of a targeted signal through the substrate were developed. Moreover, advanced concepts were introduced, such as the multimodal energy approach by tuning optical coupling from molecules to the nanoscale within complex matter composites. These approaches were based on the confinement of specific optical matter, considering molecular spectroscopics and nano-optics, from where the new concept nominated as metamaterials was generated. In this manner, fundamental and applied research by the design of hierarchical bottom-up materials, controlling molecules towards nanoplatforms and modified substrates, was proposed. Therefore, varied accurate length scales and dimensions were controlled. Finally, it showed proofs of concepts and applications of implantable, portable, and wearable devices from cutting-edge knowledge to the next generation of devices and miniaturized instrumentation.

The fast-growing field of nanotheranostics is revolutionizing cancer treatment by allowing for precise diagnosis and targeted therapy at the cellular and molecular levels. These nanoscale platforms provide considerable benefits in oncology, including improved disease and therapy specificity, lower systemic toxicity, and real-time monitoring of therapeutic outcomes. However, nanoparticles' complicated interactions with biological systems, notably the immune system, present significant obstacles for clinical translation. While certain nanoparticles can elicit favorable anti-tumor immune responses, others cause immunotoxicity, including complement activation-related pseudoallergy (CARPA), cytokine storms, chronic inflammation, and organ damage. Traditional toxicity evaluation approaches are frequently time-consuming, expensive, and insufficient to capture these intricate nanoparticle-biological interactions. Artificial intelligence (AI) and machine learning (ML) have emerged as transformational solutions to these problems. This paper summarizes current achievements in nanotheranostics for cancer, delves into the causes of nanoparticle-induced immunotoxicity, and demonstrates how AI/ML may help anticipate and create safer nanoparticles. Integrating AI/ML with modern computational approaches allows for the detection of potentially dangerous nanoparticle qualities, guides the optimization of physicochemical features, and speeds up the development of immune-compatible nanotheranostics suited to individual patients. The combination of nanotechnology with AI/ML has the potential to completely realize the therapeutic promise of nanotheranostics while assuring patient safety in the age of precision medicine.

Cobalt-based sulfides have emerged as promising candidates for next-generation high-performance anode materials for lithium-ion batteries (LIBs) due to their high theoretical specific capacity and reversible conversion reaction mechanisms. However, their practical application is hindered by volume expansion effects and relatively low rate performance. Guided by theoretical principles, this study synthesizes nanoscale Bi/CoS-C and Bi/Co₄S₃-C (denoted as Bi/CS-C) composite materials using Co and Bi₂S₃ as precursors via a solid-state ball milling method. The electrochemical properties of these materials were systematically investigated. When employed as anodes for LIBs, Bi/CoS-C and Bi/CS-C exhibit excellent rate capabilities. At current densities of 0.1, 0.5, 1, 4, and 10 A/g, the reversible capacities of Bi/CoS-C were 939.2, 730.7, 655.6, 508.1, and 319 mAh/g, respectively. In contrast, Bi/CS-C exhibited reversible capacities of 760.4, 637.6, 591.9, 484.3, and 295.4 mAh/g, respectively. Moreover, Co₄S₃, as an active component, enables superior long-cycle performance compared to CoS. After 300 cycles at 0.2 A/g, the Bi/CoS-C and Bi/CS-C electrodes retained capacities of 193.1 and 788.8 mAh/g, respectively. This study demonstrates that nanostructure design and carbon-based composite materials can effectively mitigate the volume expansion issue of cobalt-based sulfides, thereby enhancing their rate performance and cycling stability. This strategy provides new insights for the development of high-performance anode materials for lithium-ion batteries and is expected to accelerate their practical application in next-generation energy storage devices.

The MDA-MB-231 cell line is derived from triple-negative breast cancer (TNBC), representing one of the most aggressive forms of breast cancer. Innovative therapeutic strategies, including s targeted therapies using nanocarriers, hold significant promise, particularly for difficult-to-treat cancers such as TNBC. Nanoparticles have transformed the medical field by serving as advanced drug delivery systems for cancer treatment. They play a critical role in overcoming the drug resistance often associated with cancer therapies. When utilized as drug delivery vehicles, nanoparticles can specifically target cancer cells and effectively reduce or eliminate multidrug resistance. Among them, chitosan-coated magnetic nanoparticles (MNPs) have been widely explored for the loading and controlled release of various anticancer agents. In this study, we evaluated the effects of dexamethasone-loaded chitosan-coated MNPs on MDA-MB-231 cell lines. Fourier transform infrared spectroscopy and scanning electron microscopy were employed to verify the successful loading of dexamethasone onto the nanoparticles. To assess cytotoxicity, empty nanoparticles, free drug, and drug-loaded nanoparticles were tested on the cells. The results indicated that empty nanoparticles exhibited no toxic effects. The IC50 value of the free drug was 123 µg/mL, while the IC50 value of the drug-loaded nanoparticles was significantly lower, at 63 µg/mL. These findings confirmed the successful conjugation of dexamethasone to the chitosan-coated MNPs, demonstrating substantial cytotoxic effects on breast cancer cells. Although dexamethasone has been reported to exhibit both tumor-suppressive and pro-metastatic effects, its specific impact on TNBC warrants further investigation in future studies.